Compare Nutanix Inc (NTNX) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs Smith & Nephew plc — how do they compare? Nutanix Inc trades at $74.63 (market cap $19.78B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Nutanix Inc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.95% dividend while Nutanix Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nutanix Inc for 17 Days and Smith & Nephew plc for 121 Days on average.
| NTNX | SNN | |
|---|---|---|
Market Cap | $19.78B | $11.10B |
Volume | 1,717,619 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $74.63 | $37.17 |
52-Week Low | $34.41 | $26.42 |
Typical Hold Time | 17 Days | 121 Days |
Enterprise Value | $18.94B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $73.08, down 0.46% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.60 beating expectations of $0.49, and impressive net income margin expansion to 52.81% in 2026. Recent Gartner Magic Quadrant recognitions highlight competitive strength in server virtualization and container management.
The outlook remains positive with analyst consensus targeting $76.11, though elevated valuation ratios and negative ROE present risks. Key catalysts include external storage growth and AI initiatives, while supply chain pressures and competitive threats warrant monitoring. The stock's proximity to resistance at $74 suggests potential near-term consolidation before further upside.
Smith+Nephew (SNN) trades at $26.96, near its 52-week low, with bearish technical signals despite recent earnings beats. The company shows strong fundamentals with revenue growth to $6.16B in 2025 and improving profit margins of 10.08%. Recent product launches in trauma care and surgical robotics highlight innovation, but analyst sentiment remains cautious with 65% hold ratings.
Investment outlook is mixed: solid fundamentals and product pipeline offer upside, but technical weakness and analyst skepticism pose near-term risks. Key catalysts include execution on new product adoption and margin expansion, while risks involve competitive pressures and leadership transitions following the CFO's departure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
